28 October 2020

Moderna has announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has initiated a rolling review of the company’s mRNA-1273 vaccine to fight Covid-19. The announcement was made after receiving positive results from a preclinical mRNA-1273 viral challenge and the interim analysis of the Phase I study of the vaccine.

Olatec Therapeutics announced that it has enrolled it first patients into a Phase II clinical trial of the orally administered Dapansutrile capsules for treating patients with moderate Covid-19 symptoms and for evidence of early cytokine release syndrome. The trial aims to evaluate the safety and efficacy of Dapansutrile in 80 patients from various demographics.

Histogen and Amerimmune have collaborated to develop an orally active caspase inhibitor, Emricasan, to treat Covid-19. The US Food and Drug Administration (FDA) has also granted Investigational New Drug (IND) approval to Histogen to commence its Phase I study of Emricasan among mild Covid-19 patients to assess its safety and use.

Italy’s medicines regulator has approved human clinical trials for the osteoporosis drug, raloxifene to reduce Covid-19 symptoms, thereby making patients less infectious. Researchers are hoping that raloxifene will block virus replication in cells and thus slow the progress of the disease. Researchers used supercomputers to investigate approximately 400,000 molecules and more for chemical characteristics that might slow down the virus.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.